Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Nov;266(11):2734-2742.
doi: 10.1007/s00415-019-09475-x. Epub 2019 Jul 19.

Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy

Ingrid J T Herraets  1 , Jaap N E Bakers  2 , Ruben P A van Eijk  1   3 , H Stephan Goedee  1 , W Ludo van der Pol  1 , Leonard H van den Berg  4
Affiliations
Clinical Trial

Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy

Ingrid J T Herraets et al. J Neurol. 2019 Nov.

Abstract

Objective: The primary aim was to determine the safety of treatment with human immune globulin 10% with recombinant human hyaluronidase (fSCIg) compared to intravenous immunoglobulin (IVIg) in a prospective open-label study in patients with multifocal motor neuropathy (MMN).

Methods: Our study consisted of two phases: the IVIg phase (visits 1-3; 12 weeks), in which patients remained on IVIg treatment, and the fSCIg phase (visits 4-7; 36 weeks), in which patients received fSCIg treatment. After visit 3, IVIg was switched to an equivalent dose and frequency of fSCIg. Outcome measures were safety, muscle strength, disability and treatment satisfaction.

Results: Eighteen patients were enrolled in this study. Switching to fSCIg reduced the number of systemic adverse events (IVIg 11.6 vs. fSCIg 5.0 adverse events/per person-year, p < 0.02), and increased the number of local reactions at the injection site (IVIg 0 vs. fSCIg 3.3 local reactions/per person-year, p < 0.01). Overall, no significant differences in muscle strength and disability between fSCIg and IVIg were found. Treatment with fSCIg was perceived as optimal treatment option by 8 of the 17 patients (47.1%) and they continued with fSCIg after study closure because of improved independence and flexibility to administer treatment.

Conclusion: Treatment with fSCIg can be considered a safe alternative for patients with MMN on IVIg treatment. fSCIg could be a favorable option in patients who prefer self-treatment and more independency, and in patients who experience systemic adverse events on IVIg or have difficult intravenous access.

Keywords: Immunoglobulin; Multifocal motor neuropathy; Peripheral neuropathy; Safety; Treatment effect.

PubMed Disclaimer

Conflict of interest statement

IH, JB, RE—these authors declare that they have no conflict of interest. SG—receives research support from the Prinses Beatrix Spierfonds, and received a travel grant and speaker fee from Shire/Takeda. LP—receives research support from the Prinses Beatrix Spierfonds, and Stichting Spieren voor Spieren. LB—serves on scientific advisory boards for Orion, Biogen, and Cytokinetics; received an educational grant from Baxalta/Takeda; serves on the editorial boards of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration and the Journal of Neurology, Neurosurgery, and Psychiatry; and receives research support from the Prinses Beatrix Spierfonds, Netherlands ALS Foundation, The European Community’s Health Seventh Framework Programme (Grant agreement no. 259867), and The Netherlands Organization for Health Research and Development (Vici Scheme, JPND [SOPHIA, STRENGTH, ALSCare]).

Figures

Fig. 1
Fig. 1
Flowchart study. fSCIg human immune globulin 10% with recombinant human hyaluronidase, IVIg intravenous immunoglobulins, SAE serious adverse event, AE adverse event
Fig. 2
Fig. 2
Outcome measures collected per visit. Questionnaires consisted of a standardized questionnaire for adverse events, treatment satisfaction rated on a 0–10 VAS scale, Guy’s Neurological Disability Scale and Self-Evaluation Scale. fSCIg human immune globulin 10% with recombinant human hyaluronidase, HHD hand-held dynamometry, IVIg intravenous immunoglobulins, Lab laboratory tests, t time in weeks, 9 HPT 9-Hole Peg test, 10 MWT 10-meter walk test
See this image and copyright information in PMC

References

    1. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH. Multifocal motor neuropathy. Lancet Neurol. 2005;4(5):309–319. doi: 10.1016/S1474-4422(05)70074-0. - DOI - PubMed
    1. Vlam L, van der Pol WL, Cats EA, Straver DC, Piepers S, Franssen H, van den Berg LH. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol. 2011;8(1):48–58. doi: 10.1038/nrneurol.2011.175. - DOI - PubMed
    1. Joint Task Force of the E, the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision. J Peripher Nerv Syst 15 (4):295–301. doi: 10.1111/j.1529–8027.2010.00290. - PubMed
    1. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M (2005) Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2:CD004429. doi: 10.1002/14651858.CD004429.pub2 - PubMed
    1. Markvardsen LH, Harbo T. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs. J Neurol Sci. 2017;378:19–25. doi: 10.1016/j.jns.2017.04.039. - DOI - PubMed

Publication types

Substances

LinkOut - more resources